3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
22
NIH
16
NETWORK
9
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Pancreatic Neoplasms
13
Neoplasm Metastasis
10
Neoplasms
8
Lung Neoplasms
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Melanoma
4
Squamous Cell Carcinoma of Head and Neck
3
Endometrial Neoplasms
3
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic cancer, adult
1
Pancreatic Ductal Adenocarcinoma (PDAC)
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Diseases
1
Pancreatic Cancer Non-resectable
1
Pancreas Adenocarcinoma
1
Interventions
Paclitaxel
47
Carboplatin
38
liposomal doxorubicin
25
Bevacizumab
23
Gemcitabine
18
Topotecan
15
pembrolizumab
14
mirvetuximab soravtansine
11
rucaparib
8
niraparib
7
Cisplatin
7
1-dodecylpyridoxal
7
trebananib
6
Drug Therapy
6
130-nm albumin-bound paclitaxel
6
Nivolumab
5
Cyclophosphamide
5
cemiplimab
4
sarilumab
3
relacorilant
3
pazopanib
3
oregovomab
3
olaparib
3
Doxorubicin
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
tocilizumab
2
seribantumab
2
phenoxodiol
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fallopian Tube Neoplasms
×
Taxes
×
Clear all
NCT05092360
2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3
Terminated
456 enrolled
19 charts